Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Ficlatuzumab |
| Trade Name | |
| Synonyms | AV-299|SCH900105 |
| Drug Descriptions |
Ficlatuzumab (AV-299) is a monoclonal antibody that targets HGF and inhibits c-MET/HGF signaling, potentially resulting in decreased tumor growth (PMID: 23493885, PMID: 29346833, PMID: 32545260). |
| DrugClasses | HGF Antibody 4 |
| CAS Registry Number | 1174900-84-5 |
| NCIT ID | C78844 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cetuximab + Ficlatuzumab | Cetuximab Ficlatuzumab | 0 | 3 |
| Cisplatin + Ficlatuzumab | Cisplatin Ficlatuzumab | 0 | 1 |
| Cytarabine + Ficlatuzumab | Cytarabine Ficlatuzumab | 0 | 1 |
| Erlotinib + Ficlatuzumab | Erlotinib Ficlatuzumab | 0 | 1 |
| Ficlatuzumab | Ficlatuzumab | 0 | 2 |
| Ficlatuzumab + Gefitinib | Ficlatuzumab Gefitinib | 0 | 0 |
| Ficlatuzumab + Gemcitabine + Nab-paclitaxel | Ficlatuzumab Gemcitabine Nab-paclitaxel | 0 | 1 |